Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Vir Biotechnology Inc (VIR)

249 + Investors. Track Smart Money conviction in VIR. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +35
Streak
2Q ▲
Buyers last Q
71%

Smart Money Signals — VIR

Based on 250 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q
For 2 consecutive quarters, more hedge funds added VIR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
250 hedge funds hold VIR right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
📶

Steady growth — +8% more funds vs a year ago

fund count last 6Q
+18 new funds entered over the past year (+8% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟢

More buyers than sellers — 71% buying

185 buying76 selling
Last quarter: 185 funds were net buyers (66 opened a brand new position + 119 added to an existing one). Only 76 were sellers (45 trimmed + 31 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+31 vs last Q)

new funds entering per quarter
Funds opening a new VIR position: 22 → 26 → 35 → 66. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

54% of holders stayed for 2+ years

■ 54% conviction (2yr+) ■ 24% medium ■ 22% new
136 out of 250 hedge funds have held VIR for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Value +77% but shares only +20% — price-driven

Value
+77%
Shares
+20%
Last quarter: the total dollar value of institutional holdings rose +77%, but actual share count only changed +20%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
🚀

Acceleration phase — new buyers rushing in

51 → 22 → 26 → 35 → 66 new funds/Q
New funds entering each quarter: 22 → 26 → 35 → 66. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Veteran-anchored — 64% veterans vs 25% newcomers

■ 64% veterans ■ 11% 1-2yr ■ 25% new
Entry-cohort mix of 259 holders: 165 (64%) are 2+ year veterans, 29 entered 1–2 years ago, and 65 (25%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 25% AUM from major funds

25% from top-100 AUM funds
45 of 247 holders rank in the top 100 by AUM, accounting for 25% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
3.7
out of 10
Low Exit Risk
Exit risk score 3.7/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — VIR

In 2026 Q1, 185 hedge funds were net buyers of VIR (66 opened a new position, 119 added to an existing one), while 76 reduced or exited (45 trimmed, 31 sold completely) — a 71% buyer ratio, indicating clear institutional accumulation. Net buying has persisted for two consecutive quarters, a positive momentum signal. 25% of total institutional value in VIR is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +35 funds (more new holders than closures). Total institutional holders: 250.

Hedge Fund Ownership: VIR

How many hedge funds hold VIR — quarterly history vs. share price
Quarterly hedge fund ownership of VIR vs. share price

Market Analysis: VIR

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: VIR

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Vir Biotechnology Inc (VIR) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much VIR has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 85d ago
VIR
+14.1%
XLV
+2.8%

VIR outperformed XLV by +11.3% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 40d ago
VIR
+16.3%
XLV
+3.9%

Since the filing became public, VIR outperformed XLV by +12.4% .

Interpretation: The stock has meaningfully outrun its sector. The trade has partially played out; entry is at a premium to the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

25 top-rated funds 7 high-conviction
Consensus
6.1
/ 10
breadth
×
Elite
3.5
/ 10
conviction
Hedge Fund Positioning: VIR
249 + Investors

Track Smart Money conviction in VIR. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 249 215 15.81%
13F Shares 139M 116M 20.27%
Total Value $1.24B $697M 77.28%
New Positions 65 35 +30
Increased Positions 117 64 +53
Closed Positions 31 30 +1
Reduced Positions 43 77 -34
Total Calls 7 6 16.67%
Total Puts 5 2 150.0%
PUT/CALL Ratio 0.71 0.33 Neutral

Statistics: VIR

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

249 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in VIR. Verified SEC 13F-HR filings.

QUARTER:
Top 25 VIR holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 ARCH Venture Management, LLC 17.09% 12,916,663 $115.7M
2 GSK plc 12.79% 8,550,954 $76.6M
3 GordonMD Global Investments LP 9.48% 1,518,552 $13.6M
4 Superstring Capital Management LP 4.68% 730,548 $6.5M
5 Alta Partners Management Company, L.P. 3.03% 509,917 $4.6M
6 Jones Hill Capital LP 2.30% 1,198,213 $10.7M
7 Boxer Capital Management, LLC 2.20% 1,866,000 $16.7M
8 Sio Capital Management, LLC 1.93% 1,498,620 $13.4M
9 ADAR1 Capital Management, LLC 1.45% 2,744,714 $24.6M
10 Avidity Partners Management LP 1.43% 619,300 $6.3M
11 Sb Investment Advisers (uk) Ltd 1.27% 10,948,093 $98.1M
12 Soleus Capital Management, L.P. 0.73% 2,002,000 $17.9M
13 Monashee Investment Management LLC 0.49% 100,000 $896K
14 Tejara Capital Ltd 0.48% 161,789 $1.4M
15 Parkman Healthcare Partners LLC 0.46% 500,000 $4.5M
16 Act Capital Management, LLC 0.45% 64,300 $576K
17 Ikarian Capital, LLC 0.21% 293,258 $2.6M
18 Empyrean Capital Partners, LP 0.15% 527,800 $4.7M
19 Diadema Partners LP 0.14% 88,800 $796K
20 Eversept Partners, LP 0.12% 250,000 $2.2M
21 WINTON GROUP Ltd 0.12% 367,883 $3.3M
22 Headlands Technologies LLC 0.11% 103,247 $925K
23 Virtus Investment Advisers, LLC 0.10% 40,759 $365K
24 Clearstead Advisors, LLC 0.10% 1,216,400 $10.9M
25 VARCOV Co. 0.06% 19,150 $172K
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Vir Biotechnology Inc (VIR)

What does the Smart Money Trend signal show for VIR?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added VIR than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for VIR?

More buyers than sellers — 71% buying: Last quarter: 185 funds were net buyers (66 opened a brand new position + 119 added to an existing one). Only 76 were sellers (45 trimmed + 31 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for VIR holders?

Strong quality — 25% AUM from major funds: 45 of 247 holders rank in the top 100 by AUM, accounting for 25% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held VIR?

54% of holders stayed for 2+ years: 136 out of 250 hedge funds have held VIR for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Vir Biotechnology Inc (VIR) following the 2026 Q1 hedge fund 13F filings?

As of today, VIR has moved +16.3% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.9% for the XLV sector ETF — an outperformance of +12.4%. Since the quarter end (March 31, 2026), VIR has gained +14.1% vs +2.8% for XLV. The stock has meaningfully outrun its sector. The trade has partially played out; entry is at a premium to the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →